Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma

Expert Opinion on Pharmacotherapy
Mark Alan FeitelsonEva Ping Lu

Abstract

Hepatitis B virus (HBV) is a major etiologic agent of chronic liver disease (CLD) and hepatocellular carcinoma. Drugs have been developed and shown to be effective against HBV replication. These treatments are often associated with the resolution of CLD. However, they are too expensive, not well tolerated, and result in the development of resistance when given as mono or salvage therapies. In addition, most of these drugs target only the virus polymerase. To revitalize the field, drugs with other targets and combination therapies need to be developed. Major advances in HBV and liver cancer drug development over the past decade, focusing on Phase III trials and FDA-approved compounds, are presented. A number of potent nucleoside/nucleotide analogs are now available for treatment, but for the long-term management of CLD, the development of combination therapies will probably be required. Development of compounds with new virus targets will enhance the utility of combination therapies. Development of compounds to host targets altered prior to or after the development of liver cancer, as demonstrated by sorafenib, need to be developed. The goal is to devise drug cocktails that will yield sustained virus responses and halt disease p...Continue Reading

References

Oct 10, 1985·Nature·P TiollaisA Dejean
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·J Benn, R J Schneider
Mar 14, 1996·The New England Journal of Medicine·V MazzaferroL Gennari
Jul 1, 1997·Antimicrobial Agents and Chemotherapy·S F InnaimoR J Colonno
Dec 3, 1998·Antimicrobial Agents and Chemotherapy·M SeiferD N Standring
Jul 29, 1999·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·F L DumoulinU Spengler
Jul 30, 1999·Nature Medicine·J LarkinM A Feitelson
Sep 25, 1999·Journal of Cellular Physiology·M A Feitelson
Nov 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J M LlovetJ Bruix
Dec 29, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J P VilleneuveE J Heathcote
May 29, 2000·Journal of Gastroenterology and Hepatology·A Safary, J Beck
Jun 8, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·N W LeungUNKNOWN Asia Hepatitis Lamivudine Study Group
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chung-Mau LoJohn Wong
Nov 22, 2002·The New England Journal of Medicine·Andreas GeierChristoph G Dietrich
Feb 28, 2003·The New England Journal of Medicine·Stephanos J HadziyannisUNKNOWN Adefovir Dipivoxil 438 Study Group
Feb 28, 2003·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Adefovir Dipivoxil 437 Study Group
May 24, 2003·Journal of Hepatology·Eugene R SchiffUNKNOWN International Lamivudine Investigator Group
Sep 6, 2003·Liver International : Official Journal of the International Association for the Study of the Liver·Kenta SuzukiYutaka Aoyagi
Apr 6, 2004·The Surgical Clinics of North America·Mark A FeitelsonZhaorui Lian
Apr 6, 2004·The Surgical Clinics of North America·Christoph E BroelschMassimo Malago
Apr 6, 2004·The Surgical Clinics of North America·Dominique EliasMichel Ducreux
Apr 6, 2004·The Surgical Clinics of North America·Johannes H W de WiltAlexander M M Eggermont
May 25, 2004·Antimicrobial Agents and Chemotherapy·Radhakrishnan P IyerJohn D Morrey
Jun 16, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anna K NowakMichael Findlay
Sep 17, 2004·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
Oct 20, 2004·Cancer Research·Hie-Won L HannMark A Feitelson
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W YeoP J Johnson
Nov 27, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Morris Sherman, Andrew Klein
Jan 11, 2005·Lancet·Harry L A JanssenUNKNOWN Rotterdam Foundation for Liver Research
Feb 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jean S CampbellNelson Fausto
Mar 17, 2005·Frontiers in Bioscience : a Journal and Virtual Library·Mark Alan FeitelsonJingbo Pan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.